HCW Biologics Confirms 1-for-40 Reverse Stock Split Strategy
New York, Wednesday, 2 April 2025.
HCW Biologics initiates a 1-for-40 reverse stock split effective 11 April 2025 to maintain Nasdaq listing, adjusting issued shares from 44.9 million to approximately 1.1 million.
Strategic Nasdaq Compliance Move
The Miramar, Florida-based biotechnology company HCW Biologics Inc. (NASDAQ: HCWB) announced this strategic move on April 1, 2025, as part of its efforts to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share [1]. The reverse stock split represents a significant corporate action that will maintain the company’s position on The Nasdaq Capital Market, while consolidating the company’s share structure [1].
Share Structure Transformation
Under the terms of this corporate restructuring, the company will maintain its total authorized shares at 250,000,000, with the par value remaining unchanged at $0.0001 per share [1]. The most notable change will be the reduction in issued and outstanding shares, decreasing from 44,934,120 to approximately 1,123,353 shares [1]. To protect smaller shareholders, the company has implemented measures ensuring that stockholders entitled to fractional shares will receive one whole share instead [1].
Implementation Timeline
The company has already set key implementation dates in motion, having filed the necessary amendments to its Certificate of Incorporation with the Delaware Secretary of State on March 31 and April 1, 2025 [1]. The reverse stock split is scheduled to take effect on April 11, 2025, marking a pivotal moment in HCW Biologics’ corporate strategy [1]. This careful timing allows shareholders and market participants to prepare for the impending changes in the company’s capital structure.